戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 on of prior systemic therapy and presence of liver metastases.
2 ncer, both CVX-060 and regorafenib inhibited liver metastases.
3 ic tumors and to accelerate the formation of liver metastases.
4 h as hepatocellular carcinoma and colorectal liver metastases.
5 dict response to neoadjuvant chemotherapy in liver metastases.
6 and a potential target for interference with liver metastases.
7 t detection of bone lesions, lymph node, and liver metastases.
8 nagement strategies exist for neuroendocrine liver metastases.
9  of two primary CRC tumors and their matched liver metastases.
10 le toxicity profile in salvage patients with liver metastases.
11 ase recurrence after resection of colorectal liver metastases.
12 n bile ducts induced cholangiocarcinoma with liver metastases.
13 as performed in mice bearing patient-derived liver metastases.
14 eight fresh human colorectal carcinoma (CRC) liver metastases.
15 portantly, ADPh prevented the development of liver metastases.
16 y, for the detection and characterization of liver metastases.
17  patients also had synchronous resections of liver metastases.
18 ents with colorectal cancer with synchronous liver metastases.
19 fibroblasts associated with human colorectal liver metastases.
20 e quality and in the detection of colorectal liver metastases.
21 ic lineages of two CRC patients with matched liver metastases.
22  that obtained after resection of colorectal liver metastases.
23 on 538 to glycine (D538G), was identified in liver metastases.
24  for salvage patients with colorectal cancer liver metastases.
25 e identified; two presented with synchronous liver metastases.
26 erapy in patients presenting with colorectal liver metastases.
27 construction algorithms for the detection of liver metastases.
28 ased the rate of resection for IU colorectal liver metastases.
29 atocellular carcinomas, were also mutated in liver metastases.
30 y-only, 41% primary + lymph node, and 7% had liver metastases.
31  a large majority of metachronous colorectal liver metastases.
32 c targets in the prevention and treatment of liver metastases.
33 regressions in primary tumors and colorectal liver metastases.
34 a new therapeutic target in the treatment of liver metastases.
35 portant effect in the immune surveillance of liver metastases.
36 shed as a prognostic indicator in colorectal liver metastases.
37 ingly used to treat patients with colorectal liver metastases.
38 alterations in pancreatic primary tumors and liver metastases.
39 SCs to form a premetastatic niche to promote liver metastases.
40 lications of radioembolization of colorectal liver metastases.
41 loid cells can be used to target established liver metastases.
42 e of invasive tumors and no apparent lung or liver metastases.
43  to liver endothelial cells and formation of liver metastases.
44 premetastatic niche that ultimately promoted liver metastases.
45 ients with metastatic colorectal cancer with liver metastases.
46 patic peritoneal metastasis and hematogenous liver metastases.
47 vacizumab in patients with colorectal cancer liver metastases.
48 est (90)Y study for patients with colorectal liver metastases.
49 ue of hepatic USG for detecting asymptomatic liver metastases.
50 as reduced in CTC compared to tumor cells in liver metastases.
51 eived (90)Y radioembolization for colorectal liver metastases.
52 marker for metastatic activity of colorectal liver metastases.
53  glass microsphere treatments for colorectal liver metastases.
54 sed cell death in primary CTCL tumors and in liver metastases.
55 hepatocellular carcinoma and 2 patients with liver metastases (1 neuroendocrine, 1 colorectal) underw
56               Among patients with colorectal liver metastases (29 before vs 76 after implementation),
57 mor (SS-group), (2) resection of synchronous liver metastases 3 to 12 months after resection of the p
58 ETHODS Forty-nine patients with unresectable liver metastases (53% previously treated with chemothera
59 with 473 procedures (139 HCC, 198 colorectal liver metastases, 61 neuroendocrine liver metastases, an
60 ion is also prevalent in human breast cancer liver metastases, a setting in which results with anti-a
61 erapy in patients with neuroendocrine tumors liver metastases; a lower pretreatment distribution volu
62 ersus nonanatomical resection for colorectal liver metastases, according to KRAS mutational status.
63 d systemic increases in TIMP1 developed more liver metastases after injections of pancreatic cancer c
64 % of patients with colorectal cancer develop liver metastases after resection of the primary tumor, a
65 ong with the proportion of mice with diffuse liver metastases, an effect ablated by coexpression of N
66          Volumes of interest were drawn over liver metastases and aorta.
67 ning to the role of surgery in patients with liver metastases and concomitant extrahepatic disease.
68  increasing evidence to support resection of liver metastases and concurrent EHD in selected patients
69  increasing evidence to support resection of liver metastases and concurrent EHD in selected patients
70 term survival is possible after resection of liver metastases and concurrent EHD, but true cure is ra
71 term survival is possible after resection of liver metastases and concurrent EHD, but true cure is ra
72 urgery may prove to be effective at reducing liver metastases and increasing the survival benefit of
73 ted with a high rate of somatic mutations in liver metastases and inferior outcomes after hepatectomy
74        We found that human colorectal cancer liver metastases and murine gastrointestinal experimenta
75 T-PCR and immunohistochemistry in colorectal liver metastases and nontumorous-adjacent liver parenchy
76 d: (1) simultaneous resection of synchronous liver metastases and primary tumor (SS-group), (2) resec
77  number dramatically during establishment of liver metastases and were recruited from bone marrow by
78  proliferation/apoptotic rate in synchronous liver metastases and/or adjacent liver parenchyma.
79 ine patients with NETs (41 patients with 162 liver metastases, and 18 control subjects with no liver
80 lorectal liver metastases, 61 neuroendocrine liver metastases, and 75 other) for a total of 875 tumor
81 vs 1), age (<50 vs >/=50 years), presence of liver metastases, and histopathological grade (2 vs 3).
82  response to neoadjuvant chemotherapy in the liver metastases, and inhibition of this protein at both
83  colorectal liver metastases, neuroendocrine liver metastases, and other cancers.
84  pcCRC remained after adjusting for age, PS, liver metastases, and other factors (OS: HR = 1.3, P < .
85 12 using terms describing colorectal cancer, liver metastases, and surgery.
86 d in purine metabolism, were detected in 4/5 liver metastases, and the same four liver metastases sha
87 ng photothermal ablation (PTA) of colorectal liver metastases, and thus increase ablation zones.
88  growth inhibition (TGI) = 76% at 35 mg/kg), liver metastases, and tumor blood vessels compared with
89 atients with metastatic disease will develop liver metastases, and, therefore, the control of liver m
90                                              Liver metastases are a major cause of death from colorec
91 ses and murine gastrointestinal experimental liver metastases are infiltrated by neutrophils.
92      Collectively, our results indicate that liver metastases are more reliant on VEGFR-1 than lung m
93  reason for this unfavorable outcome is that liver metastases are poorly vascularized, limiting the a
94 d immediately after percutaneous ablation of liver metastases are predictors of local treatment failu
95 ent results reveal that NKT cells exacerbate liver metastases arising from intraocular melanomas.
96 cells, especially type I NKT cells, enhanced liver metastases arising from intraocular melanomas.
97                       Current treatments for liver metastases arising from primary breast and lung ca
98 expressing clones formed significantly fewer liver metastases as compared with control clones.
99 CL5-promoter activation within the stroma of liver metastases as evidenced by tumor-selective iodide
100 ur knowledge), robust MRI detection of early liver metastases as small as approximately 0.24 mm in di
101             PKLR expression was increased in liver metastases as well as in primary colorectal tumors
102 ew the existing approaches to neuroendocrine liver metastases, assess the evidence on which managemen
103                                     CUP with liver metastases associated with liver (1.44) cancer in
104 of perioperative chemotherapy for colorectal liver metastases, associations between specific agents a
105 between observers 1 and 2 for characterizing liver metastases at per-lesion analysis (kappa coefficie
106                      Two of them had already liver metastases at surgery, 13 were disease-free at las
107  During follow-up, 3 patients died, each had liver metastases at surgery.
108 pproximately 75-80% of patients present with liver metastases at the time of their diagnosis, and 20%
109 ategies for patients with bilobar colorectal liver metastases (bCRLM).
110                              Most colorectal liver metastases become refractory to chemotherapy and b
111 ected patients with nonresectable colorectal liver metastases benefit from liver transplantation and
112  an initial complete resection of colorectal liver metastases between 1992 and 2012.
113 ulted not only in a higher detection rate of liver metastases but also in a significantly higher lesi
114  for preventing the initial establishment of liver metastases but has limited application for use in
115 n be recommended for downsizing unresectable liver metastases, but not for resectable lesions, for wh
116 ereas VEGFR-1 neutralization decreased RenCa liver metastases by 31%.
117 lyst for photothermal ablation of colorectal liver metastases by increasing ablation zones.
118 e a metastatic CRC mouse model and show that liver metastases can manifest without a lymph node metas
119 )F-DCFPyL in late stages, when rare cases of liver metastases can occur.
120                   In a mouse model of spleen-liver metastases, cancer dissemination to liver was dram
121 ong-term survival to selected patients whose liver metastases cannot be removed in a single procedure
122 n oncological outcomes for colorectal cancer liver metastases (CCLM) remain inconclusive.
123 esection after chemotherapy for colon cancer liver metastases (CCLM).
124 t bevacizumab before resection of colorectal liver metastases (CLM) and to identify predictors of the
125 We hypothesized that metachronous colorectal liver metastases (CLM) have different biology after fail
126 f postoperative complications for colorectal liver metastases (CLM) in the era of RAS mutation analys
127 stage resection (TSR) of advanced colorectal liver metastases (CLM) may be the result of selection of
128 s who had a complete resection of colorectal liver metastases (CLM).
129 ve chemotherapy and resection for colorectal liver metastases (CLM).
130 ischemia (RLI) after resection of colorectal liver metastases (CLMs) is unknown to date.
131 ) after liver transplantation for colorectal liver metastases (CLMs).
132 56.8 y; range, 35-79 y) for the treatment of liver metastases (colorectal, n = 23; breast, n = 1; and
133                             For unresectable liver metastases, combination regimens result in enhance
134 creased levels of AKT2 and resulted in fewer liver metastases compared to controls in vivo.
135 ated with anti-miR-182 had a lower burden of liver metastases compared with control.
136 PGE2 had increased numbers of cecal CSCs and liver metastases compared with controls after intracecal
137 ble liver malignancies, including colorectal liver metastases (CRLM) ( 1 ).
138 luate outcomes after resection of colorectal liver metastases (CRLM) and concurrent extrahepatic dise
139 luate outcomes after resection of colorectal liver metastases (CRLM) and concurrent extrahepatic dise
140                      KRAS-mutated colorectal liver metastases (CRLM) are known to be more aggressive
141 ent of patients with simultaneous colorectal liver metastases (CRLM) includes liver-directed chemothe
142 ern multidisciplinary therapy for colorectal liver metastases (CRLM) is associated with significant m
143 in the treatment of patients with colorectal liver metastases (CRLM) is the Kirsten rat sarcoma viral
144 y-nine patients with unresectable colorectal liver metastases (CRLM) were included in a single-instit
145 A total of 141 (70%) patients had colorectal liver metastases (CRLM).
146 ion after partial hepatectomy for colorectal liver metastases (CRLM).
147 d-line treatment of patients with colorectal liver metastases (CRLM).
148 ion after partial hepatectomy for colorectal liver metastases (CRLM).
149 comes to open liver resection for colorectal liver metastases (CRLMs).
150 lorectal cancer (CRC), it is unknown whether liver metastases derive from cancer cells that first col
151  established tumors and slowed the growth of liver metastases, driven by cytotoxic T-lymphocyte-media
152 d mediastinal nodes in lung cancer and small liver metastases due to background noise.
153                We found that 80% of clinical liver metastases express a NANOG with 75% of the positiv
154                           Importantly, human liver metastases express higher CKB and SLC6A8 levels an
155 ssue from both primary colorectal tumour and liver metastases from 17 patients was subjected to prote
156 ho underwent primary resection of colorectal liver metastases from 2 major hepatobiliary units in the
157 rs, a shift in indications toward colorectal liver metastases from 53% to 77% and a reverse trend in
158 icrosphere radioembolization of unresectable liver metastases from breast cancer.
159  Clinically, immunohistochemical analysis of liver metastases from chemotherapy-naive colon cancer pa
160 rs) who underwent radioembolization to treat liver metastases from colorectal adenocarcinoma between
161 or patients with initially 1 to 4 resectable liver metastases from colorectal cancer (CRC).
162 duals with hepatocellular carcinoma (HCC) or liver metastases from colorectal cancer (LM-CRC).
163 pected of having hepatocellular carcinoma or liver metastases from colorectal cancer and were schedul
164  resectability in patients with unresectable liver metastases from colorectal cancer treated with hep
165 ring preoperative treatment of patients with liver metastases from colorectal cancer, and its predict
166  the treatment of patients with unresectable liver metastases from colorectal cancer, demonstrating a
167 cle of treatment in patients with resectable liver metastases from colorectal cancer, within a phase
168                This increase in formation of liver metastases from injected pancreatic cancer cells w
169 ve for the detection and characterization of liver metastases from NETs than T2-weighted FSE and dyna
170 unexpectedly caused a remarkable increase in liver metastases from neuroblastoma and breast cancer ce
171                         Twenty patients with liver metastases from neuroendocrine tumors underwent T1
172 e various treatment options in patients with liver metastases from neuroendocrine tumors.
173  comparison group consisted of patients with liver metastases from non-NET cancer.
174 ished PET response criteria in patients with liver metastases from pancreatic cancer after treatment
175 atic progression after radioembolization for liver metastases from pancreatic cancer.
176  before and 3 mo after radioembolization for liver metastases from pancreatic cancer.
177  or oligometastatic disease (defined as </=3 liver metastases) (group 2).
178      The proteome heterogeneity of human CRC liver metastases has a distinct, organized pattern.
179 ncreasing use of chemotherapy for colorectal liver metastases has raised awareness of the potential h
180 ting lymphocytes in primary colon tumors and liver metastases have improved outcomes.
181 athologic findings of core liver biopsies of liver metastases identified by needle localization in a
182 then, she had been treated with resection of liver metastases in 2009 and 2010, palliative combinatio
183                  Attenuation of colon cancer liver metastases in 208 patients was measured on portal
184 6 to 82 years), hemoglobin < 10 g/dL in 17%, liver metastases in 30%, median time from prior chemothe
185 icantly reduced whole body, lung, kidney and liver metastases in an experimental metastases mouse mod
186 otherapy and surgery for operable colorectal liver metastases in KRAS exon 2 wild-type patients resul
187 ase signaling, and promotes the formation of liver metastases in mice.
188 opic and open liver resection for colorectal liver metastases in the elderly.
189 ssociated with CTC shedding from established liver metastases in the training and validation cohorts.
190 (Arp2/3) is required for vessel co-option in liver metastases in vivo and that, in this setting, comb
191                 Some suggest that resectable liver metastases, in the absence of high-risk features,
192 Intraarterial therapy options for colorectal liver metastases include chemoinfusion via a hepatic art
193                     For CT26 colon carcinoma liver metastases, inhibition of both VEGFR-1 and VEGFR-2
194 a mouse model with preestablished CD46(high) liver metastases, intravenous injection of Ad5/35++ resu
195 hway mutations/chromosomal inversions in 5/5 liver metastases, irrespective of cancer types.
196 r metastases, and, therefore, the control of liver metastases is an important issue.
197                           Early detection of liver metastases is crucial to appropriately select pati
198 er curatively intended surgery of colorectal liver metastases is feasible and may significantly impro
199 atic resection of colorectal carcinoma (CRC) liver metastases is increasing, but evidence for the imp
200 ents with colorectal cancer with synchronous liver metastases is possible but is associated with a wi
201 ostic factors after resection for colorectal liver metastases is unclear.
202 ot be withheld from patients with colorectal liver metastases lacking intratumoral (99m)Tc-MAA accumu
203 in already established, experimental, murine liver metastases led to diminished metastatic growth.
204 r curatively intended surgery for colorectal liver metastases, liver recurrences occur in more than 6
205 who underwent liver transplantation (LT) for liver metastases (LM) from neuroendocrine tumors (NET) o
206 udy aimed to assess the prognostic impact of liver metastases (LM) in patients with colorectal perito
207 nt for patients with colorectal cancer (CRC) liver metastases (LM).
208  metastases vs as suppressor in prostate and liver metastases) may eventually help us to develop bett
209 -six patients with a total of 435 colorectal liver metastases (mean number of lesions +/- SD, 6.6 +/-
210                              Embolization of liver metastases might reduce symptoms of ZES although a
211 t cancer liver metastases, n = 7; colorectal liver metastases, n = 5; hepatocellular carcinoma, n = 8
212 ectable advanced liver tumors (breast cancer liver metastases, n = 7; colorectal liver metastases, n
213 ents with multifocal, bilobar neuroendocrine liver metastases (NELM) after the first transarterial ch
214 : hepatocellular carcinoma (HCC), colorectal liver metastases, neuroendocrine liver metastases, and o
215  cancer (WHO performance status 0 or 1) with liver metastases not suitable for curative resection or
216 ns of 79 colorectal tumors and 23 associated liver metastases, obtained from 2 hospitals in Spain.
217  patients with unresectable, chemorefractory liver metastases of any origin were enrolled in this pha
218          This led to inhibition of growth of liver metastases of multiple tumors regardless of their
219 ly, an analogous myeloid subset was found in liver metastases of some colorectal cancer patients.
220 growing in the liver in vivo and a subset of liver metastases of uveal melanoma patients express acti
221  sequencing identified mutations enriched in liver metastases of various cancers, including Notch pat
222 laparoscopic liver resection, for colorectal liver metastases, offers significant lower morbidity, an
223  colorectal carcinoma undergoing surgery for liver metastases or hepatocellular carcinoma.
224 ls with tumor-conditioned myeloid cells from liver metastases or myeloid cell conditioned media down-
225 nfunctioning pancreatic NET with more than 3 liver metastases or other metastases was 25 mo.
226 ngly used for the treatment of patients with liver metastases or primary liver cancer.
227 ed into either the murine spleen to generate liver metastases or tail vein to generate lung metastase
228  with non-small cell lung cancer, colorectal liver metastases, or metastatic melanoma who were scanne
229 urs in 40% of primary tumors and in most CRC liver metastases (P<0.0001).
230 lizing antibody to mice bearing experimental liver metastases phenocopied neutrophil depletion by red
231             Chemotherapy-naive patients with liver metastases plus or minus limited extrahepatic meta
232 diameter of less than 8 cm for the 2 largest liver metastases predicted time to intrahepatic progress
233 esis, GCLC, becomes overexpressed in patient liver metastases, promotes cell survival under hypoxic a
234 liver parenchyma adjacent to the synchronous liver metastases provides an angiogenic prosperous envir
235 roups of patients, together with more than 3 liver metastases, R1 resection, and extrahepatic disease
236 o the significantly higher detection rate of liver metastases rather than tumor differentiation grade
237                The majority of patients with liver metastases receive palliative chemotherapy, with a
238 tients with colorectal carcinoma and bilobar liver metastases received whole-liver radioembolization
239 m study, 56 patients were enrolled, all with liver metastases refractory to systemic therapy and inel
240 s (NETs), but detection rates, especially of liver metastases, remain limited even with PET/CT.
241                       Surgery for colorectal liver metastases results in an overall survival of about
242 r "radioembolization" and "colorectal cancer liver metastases." Results were described separately for
243 d in 4/5 liver metastases, and the same four liver metastases shared mutations in 32 genes, including
244                                   Colorectal liver metastases shed intact tumor cells with an invasiv
245  margin achieved in patients with colorectal liver metastases should now be considered the standard o
246     Pathway analyses of all mutated genes in liver metastases showed aberrant tumor necrosis factor a
247          Radioembolization for breast cancer liver metastases shows encouraging local response rates
248 not granulocytes, isolated from experimental liver metastases stimulated migration and invasion of MC
249 RC) can be accompanied by rapid outgrowth of liver metastases, suggesting a role for angiogenesis.
250 on of metastatic signature miRs similarly to liver metastases, suggesting their involvement in adapti
251 % of salvage patients with colorectal cancer liver metastases survive more than 12 mo after treatment
252 f (18)F-FLT may limit utility for imaging of liver metastases.Targeting angiogenesis has had some suc
253 venous injection of LV12 cells produced more liver metastases than QRsP-11 cells, whereas the inciden
254  transfected with CXCR4 siRNA produced fewer liver metastases than untreated uveal melanoma cells or
255               We found a marked reduction in liver metastases that correlated with a greatly reduced
256 deficient mice developed significantly fewer liver metastases that were NK-cell dependent.
257 era of effective chemotherapy for colorectal liver metastases, the association between surgical margi
258       Changes in attenuation of colon cancer liver metastases treated with (90)Y radioembolization co
259    Unresectable chemorefractory colon cancer liver metastases treated with (90)Y radioembolization in
260 f a large cohort of patients with colorectal liver metastases treated with (90)Y radioembolization us
261               Among patients with colorectal liver metastases treated with bevacizumab-containing che
262  of 82 patients with unresectable colorectal liver metastases treated with bevacizumab-containing che
263               In a mouse model of colorectal liver metastases, treatment with oxaliplatin also result
264 microenvironment of either primary tumors or liver metastases triggered regression of established tum
265         Patients with colorectal cancer with liver metastases undergo hepatic resection with curative
266           Fifty-one patients with colorectal liver metastases underwent body CT (thorax and abdomen)
267 ean: 2.2 cm +/- 1.1) metachronous colorectal liver metastases underwent ultrasonography-guided percut
268  metastases, and 18 control subjects with no liver metastases) underwent MR imaging that included DW,
269 rom explant cultures of CRC patients-derived liver metastases was associated with response to OXA + C
270  in the inhibition of liver NK resistance to liver metastases was determined by in vivo and in vitro
271                    The effect of NK cells on liver metastases was determined by selective depletion w
272                           The development of liver metastases was evaluated by histopathology.
273 stases, whereas progression of nonresectable liver metastases was observed in the chemotherapy group.
274                          The sensitivity for liver metastases was poor, and quantification of (18)F-F
275 CXCR4 siRNA transfection on the formation of liver metastases was tested by injecting transfected mel
276 low passage cultures from primary tumors and liver metastases we show that ATM loss accelerates Kras-
277                                    Increased liver metastases were also seen after treatment with the
278 years; range 43.6-66.3), with neuroendocrine liver metastases were analyzed by means of distributed p
279 ING, AND PATIENTS: A total of 234 colorectal liver metastases were analyzed from 50 patients who unde
280 tratumoral (99m)Tc-MAA uptake was rated, and liver metastases were classified according to changes in
281      A rapid tumor progression was observed: liver metastases were detected after 4 months.
282 gnosed with metastatic disease in 2009, when liver metastases were found 1 year after the primary tre
283                                      Because liver metastases were found in 7%, which may have been c
284                        At follow-up, 125 new liver metastases were found, and of these 32.8% (41 of 1
285 patients treated with liver embolization for liver metastases were found, and similar results were de
286       Unexpectedly, primary tumor volume and liver metastases were increased in 5-LO-KO mice.
287 ctable or suboptimally resectable colorectal liver metastases were randomised in a 1:1 ratio to recei
288  curative resection of at least 4 colorectal liver metastases, were selected from a prospective datab
289  cells demonstrated significant reduction in liver metastases when treated with N(1)-(3-aminopropyl)-
290 or bone metastases, distant lymph nodes, and liver metastases, whereas CT was more sensitive for lung
291  Food and Drug Administration for colorectal liver metastases, whereas institutional review board app
292 in a syngeneic tumor model resulted in fewer liver metastases, whereas PHD3 knockdown induced tumor s
293 EGFR-2 neutralization had no effect on RenCa liver metastases, whereas VEGFR-1 neutralization decreas
294 ys containing samples from CRC patients with liver metastases who had undergone hepatic resection.
295 ated the second hepatectomy in patients with liver metastases who required a 2-stage hepatectomy.
296                        With the exception of liver metastases, whole-body imaging of ER expression wi
297  However, colony size was greatly reduced in liver metastases with decreased invasion into adjacent t
298 clinical benefit in patients with colorectal liver metastases with liver-dominant disease after chemo
299 ge of the biological phenotype of colorectal liver metastases would be invaluable to inform clinical
300 , chemotherapy type (vinflunine vs taxanes), liver metastases (yes vs no), and number of prognostic f

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top